Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Surveillance for Leishmaniasis Skin Lesions in Mali

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT00344084
Recruitment Status : Completed
First Posted : June 26, 2006
Last Update Posted : November 8, 2019
Sponsor:
Information provided by:
National Institutes of Health Clinical Center (CC)

Study Description
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:

This study will examine why some people who become infected with the leishmaniasis parasite develop skin lesions and others do not. The parasite that causes leishmaniasis is transmitted by the bite of a sandfly. It can cause skin lesions that may persist for several months, spread to other parts of the body, and become infected with bacteria. Treated with medicine, leishmaniasis can be cured completely.

People 1 year of age and older who live in the Mali villages of Kemena or Sougoula may be eligible for this study.

Participants are injected with a small amount of inactive parasites into the skin of their arm. People who have a reaction to the test, and thus have been exposed to the parasite, are examined for skin lesions. Their lesions, if any, are evaluated and treated, and their participation in the study ends.

Participants who do not react to the skin test are examined for skin lesions every month for 5 months. Those who are 18 years of age or older and have mild leishmaniasis skin lesions may have a small amount of fluid injected into a lesion in order to remove parasites for laboratory analysis.

Patients' lesions may be photographed to compare what they look like before and after treatment. Lesions are treated with an ointment containing an antibiotic and a disinfectant twice a day for 20 days. The lesions are examined 1 and 3 weeks after treatment is completed to see if the disease has been cured. A few months later, the skin test is repeated to determine whether the person has been exposed to parasites over the past year.

A blood sample may be drawn from some participants, depending on whether they have a reaction to the second skin test and whether they have developed skin lesions. The sample is drawn only from patients 18-65 years of age.

Some blood drawn for the study may be used for genetic tests.


Condition or disease
Cutaneous Leishmaniasis

Detailed Description:
The overarching aim of the research program is to develop a vaccine against cutaneous leishmaniasis (CL) based on sandfly salivary proteins (SFSPs). In order to determine whether vaccination with SFSPs can reduce the subsequent incidence of Leishmania major infections or CL in humans, it is first necessary to establish baseline rates of parasite infection and disease. We have selected two rural villages in central Mali where we have readily observed CL lesions in individuals of all ages and large numbers of sandflies that are known to transmit L. major in West Africa. The main objectives of this study are to estimate a cross-sectional prevalence of L. major exposure; to determine the prevalence of CL; to determine an annual incidence rate of L. major infection; and to determine whether robust in vitro T and B cell responses to SFSPs correlate with protection against newly acquired L. major infection or CL. To meet these objectives, a standard leishmanin skin test (LST) will be administered to all residents of two Malian villages in order to identify a cohort of subjects who are at risk for newly acquired L. major. After the sandfly biting and disease transmission seasons, all subjects will be examined for the development of CL lesions every month for 5 months total. CL lesions will be treated topically with paromomycin- methylbenzethonium chloride ointment twice daily for 20 days. Response to therapy will be documented on days 28 and 42 of the protocol. After allowing adequate time for the development of delayed-type hypersensitivity responses to parasite antigens, LSTs will be re-administered to all subjects. Conversion from a negative to positive LST will be taken as evidence of newly acquired L. major infection. LST conversion data and clinical diagnosis of CL lesions will allow us to calculate both the incidence of new L. major infections and CL in our study population. In vitro T and B cell responses to SFSPs will be measured from a subset of individuals and correlated with relative resistance to both L. major infection and the development of clinically apparent lesions.
Study Design
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Observational
Actual Enrollment : 1593 participants
Official Title: Active Surveillance for Cutaneous Leishmaniasis in Mali
Study Start Date : March 16, 2006
Study Completion Date : September 17, 2012

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Leishmaniasis

Groups and Cohorts
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information


Outcome Measures
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Eligibility Criteria
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   1 Year and older   (Child, Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria
  • ELIGIBILITY CRITERIA:

Only consented volunteers who are permanent residents of Kemena or Sougoula, and who do not have known sensitivity to thiomerosal, will be invited to participate in this study. Otherwise, inclusion criteria specific for each phase of this study are as follows:

Administration of LST, April-May 2006:

Age greater than or equal to 1

Active and passive detection of CL, August-December 2006:

LST negative status in April 2006.

Aspiration of CL lesions, August-December 2006:

Age greater than or equal to18 years, AND

Presence of one or more clinically diagnosed CL lesion

Re-administration of LST in February-March 2007:

LST negative status in April 2006

Collection of whole blood for immunological studies, May 2007 - May 2008:

Age greater than or equal to 3 years and less than or equal to 65 years, AND

LST negative status in February-March 2007.

Active detection of CL, May 2007- May 2008:

LST negative status in February-March 2007.

Aspiration of CL lesions, May 2007 - May 2008:

Age greater than or equal to 3 years, AND

Presence of at least one PCR-diagnosed CL lesion.

Collection of fingerprick blood sample, January-March 2008:

Currently or previously enrolled on protocol

Re-administration of LST, June-July 2008:

LST negative status in February-March 2007.

Collection of whole blood for immunological studies, June - August 2008:

Age greater than or equal to 3 years and less than or equal to 65 years, AND

LST negative status in February-March 2007, AND

One of the following:

Conversion from negative to positive LST reaction during the study period, OR

Occurrence of greater than or equal to 1 PCR-confirmed CL lesion during 10-month survey period, regardless of June-July 2008 LST result, OR

Repeat LST negative result and absence of PCR-confirmed CL lesion during 10-month surveillance period.

Collection of whole blood from healthy volunteers naturally exposed to P. duboscqi October 2008-October 2012

Aqe greater than or equal to 11 years and less than or equal to 65 years, AND resident of Kemena or Sougoula OR patient with a Giemsa stain-confirmed CL lesion beinq evaluated and treated bY study physicians at CNAM in Bamako.

Exposure of individuals to the bites of laboratory-reared, noninfected P. duboscai October 2008-October 2012

Age greater than or equal to 1 years and less than or equal to 65 years AND resident of Kemena or Souaoula.

Dermal biopsy of DTH reactions occurring in individuals exposed to the bites of laboratory-reared, noninfected P. duboscai October 2008- October 2012

Age 18-65 years AND resident of Kemena or Souqoula.

Contacts and Locations
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00344084


Locations
Layout table for location information
Mali
Faculty of Medicine Pharmacy and Dentistry
Bamako, Mali
Sponsors and Collaborators
National Institute of Allergy and Infectious Diseases (NIAID)
Investigators
Layout table for investigator information
Principal Investigator: Rick M Fairhurst, M.D. National Institute of Allergy and Infectious Diseases (NIAID)
More Information
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information
Publications:

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Layout table for additonal information
ClinicalTrials.gov Identifier: NCT00344084    
Other Study ID Numbers: 999906121
06-I-N121
First Posted: June 26, 2006    Key Record Dates
Last Update Posted: November 8, 2019
Last Verified: September 17, 2012
Keywords provided by National Institutes of Health Clinical Center (CC):
Leishmania Major
Phlebotomus Duboscqi
Dermatology
Vector-Transmitted Disease
 Africa
Cutaneous Leishmaniasis
CL
Additional relevant MeSH terms:
Layout table for MeSH terms
Leishmaniasis
Leishmaniasis, Cutaneous
Euglenozoa Infections
Protozoan Infections
 Parasitic Diseases
Skin Diseases, Parasitic
Skin Diseases, Infectious
Skin Diseases